DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The "Ocular Cancer Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

Ocular Cancer Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for ocular cancer and comprehensive information on the therapeutics under development and key players involved in therapeutic development for retinoblastoma and uveal melanoma. It also features dormant and discontinued products.

There are seven products in active development for this indication and companies operating in this space include Ophthotech and VCN Biosciences.

Uveal melanoma, the most common intraocular tumor, is a disease in which melanocytes, found in the part of the eye called the uvea, become cancerous. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. There are 35 products in active development for this indication and companies operating in this space include Novartis and Eli Lilly.

Molecular targets acted on by products in development for ocular cancer include tumor antigens, kinases and growth factor receptors.

Scope

Which companies are the most active within each pipeline? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered:

1 Table of Contents

2 Introduction

2.1 Ocular Cancer Report Coverage

2.2 Retinoblastoma - Overview

2.3 Uveal Melanoma - Overview

3 Therapeutics Development

3.1 Retinoblastoma

3.2 Uveal Melanoma

4 Therapeutics Assessment

4.1 Retinoblastoma

4.2 Uveal Melanoma

5 Companies Involved in Therapeutics Development

5.1 Retinoblastoma

5.2 Uveal Melanoma

6 Dormant Projects

6.1 Retinoblastoma

6.2 Uveal Melanoma

7 Discontinued Products

7.1 Uveal Melanoma

8 Product Development Milestones

8.1 Retinoblastoma

8.2 Uveal Melanoma

9 Appendix

Companies Mentioned

Aeglea BioTherapeutics Inc APEIRON Biologics AG Bellicum Pharmaceuticals Inc Bristol-Myers Squibb Co Celldex Therapeutics Inc Cleveland BioLabs Inc Delcath Systems Inc Eli Lilly and Co EyePoint Pharmaceuticals Inc Iconic Therapeutics Inc Immunocore Ltd Innovation Pharmaceuticals Inc Iovance Biotherapeutics Inc Novartis AG Ophthotech Corp PEP-Therapy SAS PepVax Inc Pfizer Inc Plexxikon Inc Polaris Pharmaceuticals Inc Syndax Pharmaceuticals Inc Tesaro Inc VCN Biosciences SL

For more information about this report visit https://www.researchandmarkets.com/research/jzdtkk/ocular_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005983/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Oncology Drugs ,Transdermal and Transmucosal Drug Delivery,Optical Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 02:05 PM/DISC: 06/11/2018 02:06 PM

http://www.businesswire.com/news/home/20180611005983/en